Regencell Bioscience (NASDAQ:RGC) Shares Gap Up – Still a Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGCGet Free Report)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $27.23, but opened at $28.83. Regencell Bioscience shares last traded at $28.42, with a volume of 40,017 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Stock Analysis on RGC

Regencell Bioscience Trading Up 1.8%

The company’s 50 day simple moving average is $25.16 and its 200-day simple moving average is $18.23.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in shares of Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after purchasing an additional 384,250 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Regencell Bioscience in the second quarter valued at about $1,701,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience during the 2nd quarter worth about $768,000. XTX Topco Ltd acquired a new position in shares of Regencell Bioscience in the 3rd quarter valued at $598,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Regencell Bioscience in the 2nd quarter worth about $222,000. 0.13% of the stock is currently owned by institutional investors.

About Regencell Bioscience

(Get Free Report)

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Featured Stories

Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.